间充质干细胞治疗肺部疾病临床研究进展

The advances of mesenchymal stem cell trials for pulmonary diseases

近年来，大量临床前期实验证实间充质干细胞（MSC）通过定向归巢、分化为肺功能细胞和旁分泌机制治疗肺部疾病。在此基础上，一些关于MSC治疗肺部疾病（包括肺气肿、ARDS、特发性肺纤维化、肺支气管发育不良等）的临床试验正在研究中。本篇文章对相关临床试验进行综述，指导MSC更好更快的用于临床。

In recent years,a large number of pre-clinical experiments confirmed that the MSC can treat the lung diseases through targeted homing, differentiating of lung function cells and paracrine mechanisms. Based on the above reasons, many clinical trails on the treatment of pulmonary diseases （including emphysema, ARDS, idiopathic pulmonary fibrosis, bronchial dysplasia, etc. ） using the MSC are conducted by the researchers, this review summarizes the relevant clinical trials in order to provide some suggestions for the clincial practice.